Physician profile
Diane E King
NPI 1144496720
$6,474.11
in general payments reported to CMS, 2019-2025
15 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $660 · 2021: $1,083 · 2022: $1,635 · 2023: $1,201 · 2024: $587 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,308.41 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,274.37 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $709.45 | 2019-2022 | |
| Allergan, INC. | $705.62 | 2019-2020 | |
| Lundbeck LLC | $646.18 | 2019-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $457.25 | 2020-2023 | Trintellix |
| Corium, LLC | $347.42 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $296.98 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.99 | 2021-2022 | |
| Alkermes, INC. | $174.54 | 2021-2022 | |
| Axsome Therapeutics, INC. | $171.98 | 2023 | Auvelity |
| Shire North American Group INC | $71.95 | 2019 | |
| Orexo US, INC. | $39.08 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $30.68 | 2022-2023 | Qelbree |
| Biodelivery Sciences International, INC. | $26.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.